CK0804 for Myelofibrosis
(TREG108 Trial)

Recruiting in Palo Alto (17 mi)

+3 other locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 1

Recruiting

Sponsor: Cellenkos, Inc.

No Placebo Group

Trial Summary

What is the purpose of this trial?

To assess the safety and tolerability of CK0804 as add-on therapy in participants with myelofibrosis, with suboptimal response to ruxolitinib

Research Team

Eligibility Criteria

Adults over 18 with myelofibrosis not responding well to ruxolitinib can join this trial. They should have a life expectancy over 6 months, some remaining disease symptoms or spleen enlargement, and be able to follow the study plan. Women must test negative for pregnancy and avoid becoming pregnant; men must prevent fathering children during the study.

Inclusion Criteria

I still have signs of my disease after treatment with ruxolitinib alone.

I am over 18 years old.

I can take care of myself and am up and about more than half of my waking hours.

See 5 more

Exclusion Criteria

I refuse to receive blood transfusions.

Any condition that would interfere with full participation in the study

I have had radiation treatment to my spleen in the last 6 months.

See 8 more

Treatment Details

Interventions

CK0804 (Other)

Trial OverviewThe trial is testing CK0804 as an additional treatment for those with myelofibrosis who haven't had enough improvement from ruxolitinib alone. The goal is to see if it's safe and how well patients tolerate it when added to their current therapy.

Participant Groups

1Treatment groups

Experimental Treatment

Group I: Arm 1Experimental Treatment1 Intervention

CK0804 will be administered intravenously (IV) 100 million Treg Cells every 28 days up to 6 infusions.